Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the biotech sector, how AI is playing…
This story was published by Bloomberg. Read the full article on their site.
Read the full story at bloomberg.com(opens in a new tab)








